Figure 8.

Podocyte loss is not significantly altered in diabetic Nox5^pod+ mice. (A) Wilm’s tumor-1 (WT1; green) for glomerular podocytes in non-tg and Nox5^pod+ animals subjected to STZ or control (CTRL) injections; 4′,6-diamidino-2-phenylindole was used to stain nuclei. (B) Graphical representation of total WT1-positive nuclei per glomerulus in A. White columns are non-tg, and black columns are Nox5^pod+ (n=6 mice per group, with a minimum of 40 glomeruli per mouse). *P<0.05 non-tg STZ versus non-tg CTRL. (C) Electron micrographs of podocytes from non-tg and Nox5^pod+ animals subjected to STZ or control injections. (D) GBM thickness for non-tg STZ (white columns) and Nox5^pod+ STZ (black columns; n=3). *P=0.04. (E) Average foot process width for non-tg STZ (white columns) and Nox5^pod+ STZ (black columns; n=3). (F) Percent foot process effacement for non-tg STZ (white columns) and Nox5^pod+ STZ (black columns; n=3). *P=0.04.